Fusen Pharmaceutical Dirección

Dirección controles de criterios 2/4

El CEO de Fusen Pharmaceutical's es Dudu Cao , nombrado en Jan 2013, tiene una permanencia de 11.25 años. compensación anual total es CN¥1.91M, compuesta por 80.5% salario y 19.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 20.85% de las acciones de la empresa, por valor de HK$134.11M. La antigüedad media del equipo directivo y de la junta directiva es de 5 años y 7 años, respectivamente.

Información clave

Dudu Cao

Chief Executive Officer (CEO)

CN¥5.0m

Compensación total

Porcentaje del salario del CEO	32.4%
Permanencia del CEO	11.4yrs
Participación del CEO	20.9%
Permanencia media de la dirección	5.2yrs
Promedio de permanencia en la Junta Directiva	7.2yrs

Actualizaciones recientes de la dirección

Recent updates

Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky

May 21

Fusen Pharmaceutical Company Limited's (HKG:1652) Popularity With Investors Under Threat As Stock Sinks 27%

Mar 31

We Wouldn't Rely On Fusen Pharmaceutical's (HKG:1652) Statutory Earnings As A Guide

Feb 08

Is Fusen Pharmaceutical Company Limited's (HKG:1652) Recent Price Movement Underpinned By Its Weak Fundamentals?

Jan 18

Does Fusen Pharmaceutical (HKG:1652) Have A Healthy Balance Sheet?

Dec 28

What You Need To Know About Fusen Pharmaceutical Company Limited's (HKG:1652) Investor Composition

Dec 07

If You Had Bought Fusen Pharmaceutical (HKG:1652) Shares A Year Ago You'd Have Earned 34% Returns

Nov 20

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Dudu Cao en comparación con los beneficios de Fusen Pharmaceutical?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	CN¥5m	CN¥2m	-CN¥36m
Sep 30 2023	n/a	n/a	-CN¥24m
Jun 30 2023	n/a	n/a	-CN¥11m
Mar 31 2023	n/a	n/a	-CN¥23m
Dec 31 2022	CN¥2m	CN¥2m	-CN¥35m
Sep 30 2022	n/a	n/a	-CN¥34m
Jun 30 2022	n/a	n/a	-CN¥34m
Mar 31 2022	n/a	n/a	-CN¥9m
Dec 31 2021	CN¥2m	CN¥2m	CN¥17m
Sep 30 2021	n/a	n/a	CN¥48m
Jun 30 2021	n/a	n/a	CN¥79m
Mar 31 2021	n/a	n/a	CN¥75m
Dec 31 2020	CN¥2m	CN¥1m	CN¥70m
Sep 30 2020	n/a	n/a	CN¥67m
Jun 30 2020	n/a	n/a	CN¥65m
Mar 31 2020	n/a	n/a	CN¥59m
Dec 31 2019	CN¥548k	CN¥516k	CN¥53m
Sep 30 2019	n/a	n/a	CN¥63m
Jun 30 2019	n/a	n/a	CN¥72m
Mar 31 2019	n/a	n/a	CN¥87m
Dec 31 2018	CN¥251k	CN¥242k	CN¥102m

Compensación vs. Mercado: La compensación total de Dudu($USD691.53K) está por encima de la media de empresas de tamaño similar en el mercado Hong Kong ($USD232.55K).

Compensación vs. Ingresos: La compensación de Dudu ha aumentado mientras la empresa no es rentable.

CEO

Dudu Cao (38 yo)

11.4yrs

Permanencia

CN¥4,997,000

Compensación

Mr. Zhiming Cao, also known as Dudu Cao is the Executive Director and Chief Executive Officer of Fusen Pharmaceutical Company Limited since January 18, 2013, who is primarily responsible for the general ma...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Changcheng Cao	Executive Chairman	7.6yrs	CN¥65.00k	27.93% CN¥ 239.5m
Zhiming Cao	CEO & Executive Director	11.4yrs	CN¥5.00m	20.92% CN¥ 179.4m
Taisheng Hou	Executive Director	no data	CN¥81.00k	sin datos
Yongsheng Chi	Executive Director	no data	CN¥78.00k	sin datos
Qingfen Meng	Executive Director	no data	CN¥62.00k	sin datos
Zhen Li	Chief Financial Officer	5.2yrs	sin datos	sin datos
Tik Man Wong	Company Secretary	3.4yrs	sin datos	sin datos

5.2yrs

Permanencia media

59yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 1652 es experimentado (5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Changcheng Cao	Executive Chairman	7.6yrs	CN¥65.00k	27.93% CN¥ 239.5m
Zhiming Cao	CEO & Executive Director	11.4yrs	CN¥5.00m	20.92% CN¥ 179.4m
Taisheng Hou	Executive Director	7.2yrs	CN¥81.00k	sin datos
Yongsheng Chi	Executive Director	7.2yrs	CN¥78.00k	sin datos
Qingfen Meng	Executive Director	7.2yrs	CN¥62.00k	sin datos
Kwok Tung Lee	Independent Non-Executive Director	5.2yrs	CN¥162.00k	sin datos
Wing Chun Sze	Independent Non-Executive Director	6yrs	CN¥162.00k	sin datos
Kit Wa To	Independent Non-Executive Director	3.8yrs	CN¥162.00k	sin datos

7.2yrs

Permanencia media

57.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 1652 se considera experimentada (7 años de antigüedad promedio).

Fusen Pharmaceutical Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Fusen Pharmaceutical Company Limited, Annual General Meeting, May 28, 2024

CEO & Executive Director recently bought HK$224k worth of stock

Executive Chairman recently bought HK$84k worth of stock

CEO & Executive Director recently bought HK$1.0m worth of stock

Executive Chairman recently bought HK$1.1m worth of stock

Executive Chairman recently bought HK$918k worth of stock

Recent updates

Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky

Fusen Pharmaceutical Company Limited, Annual General Meeting, May 28, 2024

CEO & Executive Director recently bought HK$224k worth of stock

Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited Announces National Medical Products Administration of the People's Republic of China Accepts the Application for Launching Metformin Empagliflozin Tablets (I)

Fusen Pharmaceutical Company Limited's (HKG:1652) Popularity With Investors Under Threat As Stock Sinks 27%

Full year 2023 earnings released: CN¥0.05 loss per share (vs CN¥0.046 loss in FY 2022)

Fusen Pharmaceutical Company Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

First half 2023 earnings released: EPS: CN¥0.022 (vs CN¥0.009 loss in 1H 2022)

First half 2023 earnings released: EPS: CN¥0.022 (vs CN¥0.009 loss in 1H 2022)

Fusen Pharmaceutical Company Limited to Report Q2, 2023 Results on Aug 29, 2023

Fusen Pharmaceutical Company Limited Provides Group Earnings Guidance for the Six Months Ended 30 June 2023

Executive Chairman recently bought HK$84k worth of stock

CEO & Executive Director recently bought HK$1.0m worth of stock

Full year 2022 earnings released: CN¥0.046 loss per share (vs CN¥0.022 profit in FY 2021)

Executive Chairman recently bought HK$1.1m worth of stock

Executive Chairman recently bought HK$918k worth of stock

CEO & Executive Director recently bought HK$375k worth of stock

Executive Chairman recently bought HK$791k worth of stock

Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky

Executive Chairman recently bought HK$2.3m worth of stock

Less than half of directors are independent

CEO & Executive Director recently bought HK$2.2m worth of stock

Executive Chairman recently bought HK$2.0m worth of stock

CEO & Executive Director recently bought HK$2.0m worth of stock

CEO & Executive Director recently bought HK$658k worth of stock

CEO & Executive Director recently bought HK$79k worth of stock

CEO & Executive Director recently bought HK$1.9m worth of stock

CEO & Executive Director recently bought HK$1.9m worth of stock

First half 2022 earnings released: CN¥0.01 loss per share (vs CN¥0.057 profit in 1H 2021)

Fusen Pharmaceutical Company Limited Does Not Recommend Dividend for the Six Months Ended June 30, 2022

Fusen Pharmaceutical Company Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2022

Fusen Pharmaceutical Company Limited to Report First Half, 2022 Results on Aug 29, 2022

CEO & Executive Director recently bought HK$157k worth of stock

CEO & Executive Director recently bought HK$1.9m worth of stock

CEO & Executive Director recently bought HK$1.9m worth of stock

Fusen Pharmaceutical Company Limited Declares Final Dividend for the Year Ended 31 December 2021

Less than half of directors are independent

Investor sentiment improved over the past week

CEO & Executive Director recently bought HK$856k worth of stock

CEO & Executive Director recently bought HK$2.1m worth of stock

Investor sentiment deteriorated over the past week

First half 2021 earnings released: EPS CN¥0.057 (vs CN¥0.044 in 1H 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Here's Why Fusen Pharmaceutical (HKG:1652) Can Manage Its Debt Responsibly

First half 2021 earnings released: EPS CN¥0.057 (vs CN¥0.044 in 1H 2020)

Investor sentiment deteriorated over the past week

Fusen Pharmaceutical Company Limited Approves Final Dividend for the Year Ended 31 December 2020

Investor sentiment deteriorated over the past week

Full year 2020 earnings released: EPS CN¥0.089 (vs CN¥0.067 in FY 2019)

Fusen Pharmaceutical (HKG:1652) Seems To Use Debt Quite Sensibly

Full year 2020 earnings released: EPS CN¥0.09 (vs CN¥0.067 in FY 2019)

Investor sentiment improved over the past week

Fusen Pharmaceutical Company Limited to Report Fiscal Year 2020 Results on Mar 31, 2021

A Look At Fusen Pharmaceutical's (HKG:1652) Share Price Returns

New 90-day low: HK$4.17

We Wouldn't Rely On Fusen Pharmaceutical's (HKG:1652) Statutory Earnings As A Guide

Company Secretary has left the company

Fusen Pharmaceutical Company Limited Announces Executive Changes, with Effect from 29 January 2021

Is Fusen Pharmaceutical Company Limited's (HKG:1652) Recent Price Movement Underpinned By Its Weak Fundamentals?

Does Fusen Pharmaceutical (HKG:1652) Have A Healthy Balance Sheet?

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

What You Need To Know About Fusen Pharmaceutical Company Limited's (HKG:1652) Investor Composition

Market bids up stock over the past week

New 90-day high: HK$6.00

If You Had Bought Fusen Pharmaceutical (HKG:1652) Shares A Year Ago You'd Have Earned 34% Returns

Market bids up stock over the past week